35 research outputs found

    Improved Understanding of Fiber Digestibility in Ryegrasses

    Get PDF
    Dairy nutritionists have long known that forages with the same laboratory analysis could produce significantly different performance in lactating cows. Neutral detergent fiber digestibility (NDFD) may explain much of this variation. The objectives of the study described here were to demonstrate NDFD variation between varieties of ryegrass and season of harvest and to use this information as the basis for an educational Extension program. Large differences in NDFD were found among 11 varieties of ryegrass. This information was used to change the way livestock rations are balanced and it is hoped will convince grass seeds companies to focus more on fiber digestibility

    Convincing Oregon\u27s Dairy Industry They Have a Problem with Phosphorus

    Get PDF
    Dairy nutritionists historically balanced milk cow rations for phosphorus at .45 to .5 % DM of the total ration. New studies have shown a high producing milk cow only requires a diet at .38% DM. Thirty-seven farms were studied to determine and compare P feeding levels in Oregon. The results of the project were then incorporated into educational programs. The average farm studied was over feeding by 18%. Eighty-nine percent of producers surveyed indicated this project increased their understanding of the problem we face as an industry. Approximately 50% of producers participating reduced P feeding on their farm

    A Generative Programming Approach to Developing Pervasive Computing Systems

    Get PDF
    International audienceDeveloping pervasive computing applications is a difficult task because it requires to deal with a wide range of issues: heterogeneous devices, entity distribution, entity coordination, low-level hardware knowledge... Besides requiring various areas of expertise, programming such applications involves writing a lot of administrative code to glue technologies together and to interface with both hardware and software components. This paper proposes a generative programming approach to providing programming, execution and simulation support dedicated to the pervasive computing domain. This approach relies on a domain-specific language, named DiaSpec, dedicated to the description of pervasive computing systems. Our generative approach factors out features of distributed systems technologies, making DiaSpec-specified software systems portable. The DiaSpec compiler is implemented and has been used to generate dedicated programming frameworks for a variety of pervasive computing applications, including detailed ones to manage the building of an engineering school

    Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

    Get PDF
    BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

    Java RMI: remote method invocation

    No full text
    corecore